Related Experiment Video

Updated: Jun 2, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Mechanisms of antiangiogenic-induced arterial hypertension

Jean-Jacques Mourad1, Bernard I Levy

  • 1Department of Internal Medicine and Arterial Hypertension, Avicenne Hospital, 125 Rue de Stalingrad, 93000 Bobigny, France. jean-jacques.mourad@avc.aphp.fr

Current Hypertension Reports
|April 12, 2011
PubMed

Insights

Antiangiogenic therapy, targeting vascular endothelial growth factor (VEGF), can cause hypertension. This blood pressure increase may indicate better treatment effectiveness and prognosis in cancer patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Cardiology

Background:

  • Antiangiogenic therapy is crucial for treating solid tumors.
  • Vascular endothelial growth factor (VEGF) is a key target due to its role in angiogenesis.
  • Hypertension is a frequent side effect of antiangiogenic drugs.

Purpose of the Study:

  • To explore the relationship between antiangiogenic therapy and hypertension.
  • To understand the mechanisms behind therapy-induced hypertension.
  • To evaluate hypertension as a potential marker for treatment efficacy.

Main Methods:

  • Review of clinical trials involving antiangiogenic agents.
  • Analysis of reported incidence of hypertension.
  • Exploration of proposed pathophysiological mechanisms.

Main Results:

  • Hypertension incidence in trials ranged from 11% to 43%.
  • Mechanisms include endothelial dysfunction and capillary rarefaction.
  • Early blood pressure elevation is linked to improved outcomes.

Conclusions:

  • Hypertension is a common and significant side effect of antiangiogenic therapy.
  • The exact mechanisms of hypertension require further investigation.
  • Monitoring blood pressure may offer insights into treatment response and patient prognosis.

More Related Videos

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

2.5D Model for Ex Vivo Mechanical Characterization of Sprouting Angiogenesis in Living Tissue10:00

2.5D Model for Ex Vivo Mechanical Characterization of Sprouting Angiogenesis in Living Tissue

Published on: February 28, 2025

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...